Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2 - PubMed (original) (raw)
Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2
Richard I Hogrefe et al. Nucleosides Nucleotides Nucleic Acids. 2006.
Abstract
A blunt-ended 19-mer short interfering hybrid (siHybrid) (H) comprised of sense-DNA/antisense-RNA targeting HER-2 mRNA was encapsulated in a liposomal nanoplex with anti-transferrin receptor single-chain antibody fragment (TfRscFv) as the targeting moiety for clinically relevant tumor-specific delivery. In vitro delivery to a human pancreatic cell line (PANC-1) was shown to exhibit sequence-specific inhibition of 48-h cell growth with an IC50 value of 37 nM. The inhibitory potency of this siHybrid was increased (IC50 value of 7.8 nM) using a homologous chemically modified siHybrid (mH) in which the 19-mer sense strand had the following pattern of 2 '-deoxyinosine (dI) and 2 '-O-methylribonucleotide (2 '-OMe) residues: 5'-d(TITIT)-2'OMe(GCGGUGGUU)-d(GICIT). These modifications were intended to favor antisense strand-mediated RNAi while mitigating possible sense strand-mediated off-target effects and RNase H-mediated cleavage of the antisense RNA strand. The presently reported immunoliposomal delivery system was successfully used in vivo to inhibit HER-2 expression, and thus induce apoptosis in human breast carcinoma tumors (MDA-MB-435) in mice upon repeated i.v. treatment at a dose of 3 mg/kg of H or mH. The in vivo potency of modified siHybrid mH appeared to be qualitatively greater than that of H, as was the case in vitro.
Similar articles
- Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. Pirollo KF, et al. Cancer Res. 2007 Apr 1;67(7):2938-43. doi: 10.1158/0008-5472.CAN-06-4535. Cancer Res. 2007. PMID: 17409398 - Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC, Jiang XP, Elliott RL, Head JF. Yang DC, et al. Anticancer Res. 2001 May-Jun;21(3B):1777-87. Anticancer Res. 2001. PMID: 11497259 - Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Yoshizawa T, et al. Eur J Pharm Biopharm. 2008 Nov;70(3):718-25. doi: 10.1016/j.ejpb.2008.06.026. Epub 2008 Jul 4. Eur J Pharm Biopharm. 2008. PMID: 18647651 - Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M. Pastorino F, et al. Clin Cancer Res. 2003 Oct 1;9(12):4595-605. Clin Cancer Res. 2003. PMID: 14555535 - [Small interference RNAs directed against KDR gene inhibit the proliferation of breast cancer cells in vitro and in vivo].
Zhang XJ, Ge YL, Hou L, Li Q. Zhang XJ, et al. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008 Jan;24(1):58-61. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008. PMID: 18177622 Review. Chinese.
Cited by
- Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.
Bramsen JB, Kjems J. Bramsen JB, et al. Front Genet. 2012 Aug 20;3:154. doi: 10.3389/fgene.2012.00154. eCollection 2012. Front Genet. 2012. PMID: 22934103 Free PMC article. - Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
Spänkuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K. Spänkuch B, et al. Neoplasia. 2008 Mar;10(3):223-34. doi: 10.1593/neo.07916. Neoplasia. 2008. PMID: 18320067 Free PMC article. - Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Aigner A. Aigner A. Appl Microbiol Biotechnol. 2007 Aug;76(1):9-21. doi: 10.1007/s00253-007-0984-y. Epub 2007 Apr 25. Appl Microbiol Biotechnol. 2007. PMID: 17457539 Free PMC article. Review. - Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.
Ahmadzada T, Reid G, McKenzie DR. Ahmadzada T, et al. Biophys Rev. 2018 Feb;10(1):69-86. doi: 10.1007/s12551-017-0392-1. Epub 2018 Jan 11. Biophys Rev. 2018. PMID: 29327101 Free PMC article. Review. - Progress toward in vivo use of siRNAs-II.
Rettig GR, Behlke MA. Rettig GR, et al. Mol Ther. 2012 Mar;20(3):483-512. doi: 10.1038/mt.2011.263. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186795 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous